{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:52:32Z","timestamp":1790070752419,"version":"4.0.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13023-016-0503-2","type":"journal-article","created":{"date-parts":[[2016,8,26]],"date-time":"2016-08-26T01:31:08Z","timestamp":1472175068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues"],"prefix":"10.1186","volume":"11","author":[{"given":"Christian J.","family":"Hendriksz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth I.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne G.","family":"Kircher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Orchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Southall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,26]]},"reference":[{"issue":"Suppl 5","key":"503_CR1","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","volume":"50","author":"J Muenzer","year":"2011","unstructured":"Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50 Suppl 5:v4\u2013v12.","journal-title":"Rheumatology (Oxford)"},{"key":"503_CR2","unstructured":"Neufeld EF, Muenzer J. The mucopolysaccharidoses. 2001;8:3421\u20133452."},{"key":"503_CR3","first-page":"59","volume":"15","author":"C Lavery","year":"2015","unstructured":"Lavery C, Hendriksz C. Mortality in patients with Morquio syndrome A. JIMD Rep. 2015;15:59\u201366.","journal-title":"JIMD Rep"},{"key":"503_CR4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","volume":"32","author":"SA Jones","year":"2009","unstructured":"Jones SA, Alm\u00e1ssy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II - a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009;32:534\u201343.","journal-title":"J Inherit Metab Dis"},{"key":"503_CR5","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/ajmg.a.36584","volume":"164A","author":"R Giugliani","year":"2014","unstructured":"Giugliani R, Lampe C, Guffon N, Ketteridge D, Le\u00e3o-Teles E, Wraith JE, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)-10-year follow-up of patients who previously participated in an MPS VI survey study. Am J Med Genet A. 2014;164A:1953\u201364.","journal-title":"Am J Med Genet A"},{"key":"503_CR6","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0277-9536(98)00009-4","volume":"46","author":"The WHOQOL Group","year":"1998","unstructured":"The WHOQOL Group. The World Health Organization Quality of Life Assessment (WHOQOL). Development and psychometric properties. Soc Sci Med. 1998;46:1569\u201385.","journal-title":"Soc Sci Med"},{"key":"503_CR7","volume-title":"Measuring healthy days: Population assessment of health-related quality of life","author":"Centers for Disease Control and Prevention","year":"2000","unstructured":"Centers for Disease Control and Prevention. Measuring healthy days: Population assessment of health-related quality of life. Atlanta: Centers for Disease Control and Prevention; 2000. http:\/\/www.cdc.gov\/hrqol\/pdfs\/mhd.pdf . Accessed June 2016."},{"key":"503_CR8","first-page":"32","volume":"9","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Lavery C, Coker M, Kalkan Ucar S, Jain M, Bell L, et al. The burden endured by caregivers of patients with morquio a syndrome: results from an international patient-reported outcomes survey. JIEMS. 2014;9:32.","journal-title":"JIEMS"},{"key":"503_CR9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10545-012-9459-0","volume":"36","author":"CJ Hendriksz","year":"2013","unstructured":"Hendriksz CJ, Al-Jawad M, Berger KI, Hawley SM, Lawrence R, Mc Ardle C, et al. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis. 2013;36:309\u201322.","journal-title":"J Inherit Metab Dis"},{"key":"503_CR10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1100\/tsw.2003.88","volume":"3","author":"KL Bergwerk","year":"2003","unstructured":"Bergwerk KL, Rabinowitz YS, Falk RE. Quality of life related to visual function in three young adults with mucopolysaccharidoses. ScientificWorldJournal. 2003;3:922\u20139.","journal-title":"ScientificWorldJournal"},{"key":"503_CR11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","volume":"109","author":"P Harmatz","year":"2013","unstructured":"Harmatz P, Mengel KE, Giugliani R, Valayannopoulos V, Lin SP, Parini R, et al. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109:54\u201361.","journal-title":"Mol Genet Metab"},{"key":"503_CR12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/138920111795542615","volume":"12","author":"S Tomatsu","year":"2011","unstructured":"Tomatsu S, Monta\u00f1o AM, Oikawa H, Rowan DJ, Smith M, Barrera L, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011;12:931\u201345.","journal-title":"Curr Pharm Biotechnol"},{"key":"503_CR13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.a.30579","volume":"134A","author":"SJ Swiedler","year":"2005","unstructured":"Swiedler SJ, Beck M, Bajbouj M, Giugliani R, Schwartz I, Harmatz P, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet. 2005;134A:144\u201350.","journal-title":"Am J Med Genet"},{"key":"503_CR14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","volume":"30","author":"AM Monta\u00f1o","year":"2007","unstructured":"Monta\u00f1o AM, Tomatsu S, Gottesman GS, Smith M, Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165\u201374.","journal-title":"J Inherit Metab Dis"},{"key":"503_CR15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10545-014-9737-0","volume":"38","author":"MMG Brands","year":"2015","unstructured":"Brands MMG, G\u00fcng\u00f6r D, van den Hout JMP, Karstens FPJ, Oussoren E, Plug I, et al. Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey. J Inherit Metab Dis. 2015;38:323\u201331.","journal-title":"J Inherit Metab Dis"},{"key":"503_CR16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/8904_2012_179","volume":"9","author":"R Aslam","year":"2013","unstructured":"Aslam R, van Bommel AC, Hendriksz CJ, Jester A. Subjective and objective assessment of hand function in mucopolysaccharidosis IVa patients. JIMD Rep. 2013;9:59\u201365.","journal-title":"JIMD Rep"},{"key":"503_CR17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/PRM-2010-0103","volume":"3","author":"K White","year":"2010","unstructured":"White K, Kim T, Neufeld JA. Clinical assessment and treatment of carpal tunnel syndrome in the mucopolysaccharidoses. J Pediatr Rehabil Med. 2010;3:57\u201362.","journal-title":"J Pediatr Rehabil Med"},{"key":"503_CR18","unstructured":"The self-care tool kit. http:\/\/www.nhs.uk\/Planners\/yourhealth\/Documents\/Self%20Care%20Toolkit%20Booklet%20-%20Oct%2010%20-%20READ.pdf . Accessed 21 Apr 2016."},{"key":"503_CR19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1477-7525-8-89","volume":"8","author":"LC Doward","year":"2010","unstructured":"Doward LC, Gnanasakthy A, Baker MG. Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes. 2010;8:89.","journal-title":"Health Qual Life Outcomes"},{"key":"503_CR20","unstructured":"The Patient Reported Outcomes and Quality of Life Instrument database (PROQOLID). http:\/\/www.proqolid.org\/ . Accessed 10 July 2015."},{"key":"503_CR21","unstructured":"The On-Line Guide to Quality-of-Life Assessment. http:\/\/www.OLGA-QoL.com . Accessed 21 Apr 2016."},{"key":"503_CR22","first-page":"92","volume":"13","author":"A Riazi","year":"2006","unstructured":"Riazi A. Patient-reported outcome measures in multiple sclerosis. Int MS J. 2006;13:92\u20139.","journal-title":"Int MS J"},{"key":"503_CR23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","volume":"123","author":"LA Clarke","year":"2009","unstructured":"Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123:229\u201340.","journal-title":"Pediatrics"},{"key":"503_CR24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","volume":"144","author":"P Harmatz","year":"2004","unstructured":"Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, Plecko B, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004;144:574\u201380.","journal-title":"J Pediatr"},{"key":"503_CR25","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"P Harmatz","year":"2005","unstructured":"Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48\u00a0weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681\u20139.","journal-title":"Pediatrics"},{"key":"503_CR26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"P Harmatz","year":"2006","unstructured":"Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, S\u00e1 Miranda MC, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533\u20139.","journal-title":"J Pediatr"},{"key":"503_CR27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1750-1172-8-101","volume":"8","author":"M Raluy-Callado","year":"2013","unstructured":"Raluy-Callado M, Chen WH, Whiteman DAH, Fang J, Wiklund I. The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet J Rare Dis. 2013;8:101.","journal-title":"Orphanet J Rare Dis"},{"key":"503_CR28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-9-32","volume":"9","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Lavery C, Coker M, Ucar SK, Jain M, Bell L, et al. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis. 2014;9:32.","journal-title":"Orphanet J Rare Dis"},{"key":"503_CR29","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/j.ymgme.2014.12.104","volume":"114","author":"P Harmatz","year":"2015","unstructured":"Harmatz P, Treadwell M, Burton BK, Mitchell J, Muschol N, Jones S, Pastores G, Lau H, Sparkes R, Sutton VR, Genter F, Haller C, Shaywitz A. Impact of elosulfase alfa on pain in patients with Morquio syndrome type A. Mol Genet Metab. 2015;114:S51\u20132.","journal-title":"Mol Genet Metab"},{"key":"503_CR30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/8904_2014_396","volume":"20","author":"N Ali","year":"2015","unstructured":"Ali N, Cagle S. Psychological health in adults with morquio syndrome. JIMD Rep. 2015;20:87\u201393.","journal-title":"JIMD Rep"},{"key":"503_CR31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1442-200X.2008.02652.x","volume":"51","author":"I Kuratsubo","year":"2009","unstructured":"Kuratsubo I, Suzuki Y, Orii KO, Kato T, Orii T, Kondo N. Psychological status of patients with mucopolysaccharidosis type II and their parents. Pediatr Int. 2009;51:41\u20137.","journal-title":"Pediatr Int"},{"key":"503_CR32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ymgme.2014.08.012","volume":"114","author":"CJ Hendriksz","year":"2015","unstructured":"Hendriksz CJ, Giugliani R, Harmatz P, Mengel E, Guffon N, Valayannopoulos V, et al. Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial. Mol Genet Metab. 2015;114:178\u201385.","journal-title":"Mol Genet Metab"},{"key":"503_CR33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human a-L-iduronidase (laronidase). J Pediatr. 2004;144:581\u20138.","journal-title":"J Pediatr"},{"key":"503_CR34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.braindev.2006.08.015","volume":"29","author":"T Kato","year":"2007","unstructured":"Kato T, Kato Z, Kuratsubo I, Ota T, Orii T, Kondo N, et al. Evaluation of ADL in patients with Hunter disease using FIM score. Brain Dev. 2007;29:298\u2013305.","journal-title":"Brain Dev"},{"key":"503_CR35","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/j.1651-2227.2011.02522.x","volume":"101","author":"J Marucha","year":"2012","unstructured":"Marucha J, Jurecka A, Syczewska M, R\u00f3zdzynska-Swiatkowska A, Tylki-Szymanska A. Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status. Acta Paediatr. 2012;101:e183\u20138.","journal-title":"Acta Paediatr"},{"key":"503_CR36","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s10897-013-9665-4","volume":"23","author":"M Needham","year":"2014","unstructured":"Needham M, Packman W, Rappoport M, Quinn N, Cordova M, Macias S, et al. MPS II: adaptive behavior of patients and impact on the family system. J Genet Couns. 2014;23:330\u20138.","journal-title":"J Genet Couns"},{"key":"503_CR37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymgmr.2016.03.005","volume":"7","author":"EG Shapiro","year":"2016","unstructured":"Shapiro EG, Rudser K, Ahmed A, Steiner RD, Delaney KA, Yund B, et al. A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II. Mol Genet Metab Rep. 2016;7:32\u20139.","journal-title":"Mol Genet Metab Rep"},{"key":"503_CR38","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","volume":"127","author":"JB Holt","year":"2011","unstructured":"Holt JB, Poe MD, Escolar ML. Natural progression of neurological disease in mucopolysaccharidosis type II. Pediatrics. 2011;127:e1258\u20131265.","journal-title":"Pediatrics"},{"key":"503_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/8904_2015_521","author":"AS Kunin-Batson","year":"2016","unstructured":"Kunin-Batson AS, Shapiro EG, Rudser KD, Lavery CA, Bjoraker KJ, Jones SA, et al. Long-term cognitive and functional outcomes in children with mucopolysaccharidosis (MPS)-IH (hurler syndrome) treated with hematopoietic cell transplantation. JIMD Rep. 2016. doi: 10.1007\/8904_2015_521 .","journal-title":"JIMD Rep"},{"key":"503_CR40","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00004703-200608000-00002","volume":"27","author":"KJ Bjoraker","year":"2006","unstructured":"Bjoraker KJ, Delaney K, Peters C, Krivit W, Shapiro EG. Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation. J Dev Behav Pediatr. 2006;27:290\u20136.","journal-title":"J Dev Behav Pediatr"},{"key":"503_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2326409815576188","volume":"3","author":"C Lampe","year":"2015","unstructured":"Lampe C, Jain M, Olaye A, Meesen B, Decker C, Mengel E. Relationship between patient-reported outcomes and clinical outcomes in patients with Morquio A syndrome. J Inborn Error Metab Screen. 2015;3:1\u20138.","journal-title":"J Inborn Error Metab Screen"},{"key":"503_CR42","unstructured":"Lavery C, Wedehase B, Graham S, Harmatz P, Hendriksz CJ. Impact of Mucopolysaccharidosis on Daily living, Employment, General Health and Parenthood of Adult Patients. Poster presented at WORLDSymposium 2015; February 9\u201313, 2015; Orlando, FL."},{"key":"503_CR43","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10897-014-9791-7","volume":"24","author":"M Needham","year":"2015","unstructured":"Needham M, Packman W, Quinn N, Rappoport M, Aoki C, Bostrom A, et al. Health-related quality of life in patients with MPS II. J Genet Couns. 2015;24:635\u201344.","journal-title":"J Genet Couns"},{"key":"503_CR44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2013.02.013","volume":"109","author":"MMMG Brands","year":"2013","unstructured":"Brands MMMG, Oussoren E, Ruijter GJG, Vollebregt AAM, van den Hout HMP, Joosten KFM, et al. Up to five years experience with 11 mucopolysaccharidosis type VI patients. Mol Genet Metab. 2013;109:70\u20136.","journal-title":"Mol Genet Metab"},{"key":"503_CR45","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","volume":"37","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Burton B, Fleming TR, Harmatz P, Hughes D, Jones SA, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014;37:979\u201390.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 5","key":"503_CR46","doi-asserted-by":"crossref","first-page":"v49","DOI":"10.1093\/rheumatology\/ker396","volume":"50","author":"V Valayannopoulos","year":"2011","unstructured":"Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50 Suppl 5:v49\u201359.","journal-title":"Rheumatology (Oxford)"},{"key":"503_CR47","first-page":"89","volume":"3","author":"C Decker","year":"2010","unstructured":"Decker C, Yu Z, Giugliani R, Schwartz IVD, Guffon N, Teles EL, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med. 2010;3:89\u2013100.","journal-title":"J Pediatr Rehabil Med"},{"key":"503_CR48","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10545-012-9481-2","volume":"36","author":"E Braunlin","year":"2013","unstructured":"Braunlin E, Rosenfeld H, Kampmann C, Johnson J, Beck M, Giugliani R, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme\u00ae) therapy. J Inherit Metab Dis. 2013;36:385\u201394.","journal-title":"J Inherit Metab Dis"},{"key":"503_CR49","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/pr.2015.169","volume":"78","author":"SA Jones","year":"2015","unstructured":"Jones SA, Bialer M, Parini R, Martin K, Wang H, Yang K, et al. Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5\u00a0years. Pediatr Res. 2015;78:717\u201322.","journal-title":"Pediatr Res"},{"key":"503_CR50","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/gim.2014.25","volume":"16","author":"M Beck","year":"2014","unstructured":"Beck M, Arn P, Giugliani R, Muenzer J, Okuyama T, Taylor J, et al. The natural history of MPS I: global perspectives from the MPS I Registry. Genet Med. 2014;16:759\u201365.","journal-title":"Genet Med."},{"key":"503_CR51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","volume":"107","author":"A Tanaka","year":"2012","unstructured":"Tanaka A, Okuyama T, Suzuki Y, Sakai N, Takakura H, Sawada T, et al. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab. 2012;107:513\u201320.","journal-title":"Mol Genet Metab"},{"key":"503_CR52","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","volume":"90","author":"M Sifuentes","year":"2007","unstructured":"Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6\u00a0years. Mol Genet Metab. 2007;90:171\u201380.","journal-title":"Mol Genet Metab"},{"key":"503_CR53","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10545-010-9059-9","volume":"33","author":"A Tylki-Szymanska","year":"2010","unstructured":"Tylki-Szymanska A, Marucha J, Jurecka A, Syczewska M, Czartoryska B. Efficacy of recombinant human a-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis. 2010;33:151\u20137.","journal-title":"J Inherit Metab Dis"},{"key":"503_CR54","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/1529-0131(200007)43:7<1478::AID-ANR10>3.0.CO;2-M","volume":"43","author":"M Kosinski","year":"2000","unstructured":"Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43:1478\u201387.","journal-title":"Arthritis Rheum"},{"key":"503_CR55","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","volume":"13","author":"J Muenzer","year":"2011","unstructured":"Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13:95\u2013101.","journal-title":"Genet Med"},{"issue":"Suppl 3","key":"503_CR56","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1007\/s10545-010-9212-5","volume":"33","author":"HY Lin","year":"2010","unstructured":"Lin HY, Chen MR, Chuang CK, Chen CP, Lin DS, Chien YH, et al. Enzyme replacement therapy for mucopolysaccharidosis VI-experience in Taiwan. J Inherit Metab Dis. 2010;33 Suppl 3:S421\u20137.","journal-title":"J Inherit Metab Dis"},{"key":"503_CR57","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1017\/S0012162206000673","volume":"48","author":"E Davis","year":"2006","unstructured":"Davis E, Waters E, Mackinnon A, Reddihough D, Graham HK, Mehmet-Radji O, et al. Paediatric quality of life instruments: a review of the impact of the conceptual framework on outcomes. Dev Med Child Neurol. 2006;48:311\u20138.","journal-title":"Dev Med Child Neurol"},{"key":"503_CR58","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1524-4733.2007.00293.x","volume":"11","author":"M Solans","year":"2008","unstructured":"Solans M, Pane S, Estrada MD, Serra-Sutton V, Berra S, Herdman M, et al. Health-related quality of life measurement in children and adolescents: a systematic review of generic and disease-specific instruments. Value Health. 2008;11:742\u201364.","journal-title":"Value Health"},{"key":"503_CR59","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/jpepsy\/jsn038","volume":"33","author":"TM Palermo","year":"2008","unstructured":"Palermo TM, Long AC, Lewandowski AS, Drotar D, Quittner AL, Walker LS. Evidence-based assessment of health-related quality of life and functional impairment in pediatric psychology. J Pediatr Psychol. 2008;33:983\u201396.","journal-title":"J Pediatr Psychol"},{"key":"503_CR60","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/ajmg.a.37172","volume":"167A","author":"BK Burton","year":"2015","unstructured":"Burton BK, Berger KI, Lewis GD, Tarnopolsky M, Treadwell M, Mitchell JJ, et al. Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: a randomized, double-blind, pilot study. Am J Med Genet A. 2015;167A:2272\u201381.","journal-title":"Am J Med Genet A"},{"key":"503_CR61","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.pmn.2013.03.002","volume":"15","author":"E Jacob","year":"2014","unstructured":"Jacob E, Mack AK, Savedra M, Van Cleve L, Wilkie DJ. Adolescent pediatric pain tool for multidimensional measurement of pain in children and adolescents. Pain Manag Nurs. 2014;15:694\u2013706.","journal-title":"Pain Manag Nurs"},{"key":"503_CR62","unstructured":"The Brief Pain Inventory. MD Anderson Cancer Society. http:\/\/www.mdanderson.org\/education-and-research\/departments-programs-and-labs\/departments-and-divisions\/symptom-research\/symptom-assessment-tools\/brief-pain-inventory.html . Accessed 21 Apr 2016."},{"key":"503_CR63","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0304-3959(02)00179-3","volume":"99","author":"LM Breau","year":"2002","unstructured":"Breau LM, McGrath PJ, Camfield CS, Finley GA. Psychometric properties of the non-communicating children\u2019s pain checklist-revised. Pain. 2002;99:349\u201357.","journal-title":"Pain"},{"key":"503_CR64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.1790050303","volume":"5","author":"DR Ramey","year":"1992","unstructured":"Ramey DR, Raynauld JP, Fries JF. The health assessment questionnaire 1992: status and review. Arthritis Care Res. 1992;5:9\u201329.","journal-title":"Arthritis Care Res"},{"key":"503_CR65","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.1780371209","volume":"37","author":"G Singh","year":"1994","unstructured":"Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37:761\u20139.","journal-title":"Arthritis Rheum"},{"key":"503_CR66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/PRM-2012-0194","volume":"5","author":"NR Guarany","year":"2012","unstructured":"Guarany NR, Schwartz IVD, Guarany FC, Giugliani R. Functional capacity evaluation of patients with mucopolysaccharidosis. J Pediatr Rehabil Med. 2012;5:37\u201346.","journal-title":"J Pediatr Rehabil Med"},{"key":"503_CR67","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/PRM-2010-0100","volume":"3","author":"M Beck","year":"2010","unstructured":"Beck M, Muenzer J, Scarpa M. Evaluation of disease severity in mucopolysaccharidoses. J Pediatr Rehabil Med. 2010;3:39\u201346.","journal-title":"J Pediatr Rehabil Med"},{"key":"503_CR68","unstructured":"Scales of Independent Behavior-Revised. http:\/\/www.hmhco.com\/hmh-assessments\/other-clinical-assessments\/sib-r#sthash.hZuzuTRo.dpuf . Accessed May 2016."},{"key":"503_CR69","unstructured":"EuroQol Group. EQ-5D-5L User Guide. http:\/\/www.euroqol.org\/about-eq-5d\/publications\/user-guide.html . Accessed 21 Apr 2016 & http:\/\/www.euroqol.org\/about-eq-5d\/valuation-of-eq-5d.html . Accessed 21 Apr 2016."},{"key":"503_CR70","unstructured":"SF-63.org. http:\/\/www.sf-36.org\/tools\/sf36.shtml . Accessed 21 Apr 2016."},{"key":"503_CR71","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-7525-4-26","volume":"4","author":"JW Varni","year":"2006","unstructured":"Varni JW, Burwinkle TM. The PedsQL\u2122 as a patient-reported outcome in children and adolescents with attention-deficit\/hyperactivity disorder: a population-based study. Health Qual Life Outcomes. 2006;4:26.","journal-title":"Health Qual Life Outcomes"},{"key":"503_CR72","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/adc.2003.048645","volume":"90","author":"EM Bunge","year":"2005","unstructured":"Bunge EM, Essink-Bot ML, Kobussen MPHM, van Suijlekom-Smit LWA, Moll HA, Raat H. Reliability and validity of health status measurement by the TAPQOL. Arch Dis Child. 2005;90:351\u20138.","journal-title":"Arch Dis Child"},{"key":"503_CR73","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/eurpub\/9.3.188","volume":"9","author":"EGH Verrips","year":"1999","unstructured":"Verrips EGH, Vogels TGC, Koopman HM, Theunissen NCM, Kamphuis RP, Fekkes M, et al. Measuring health-related quality of life in a child population. Eur J Public Health. 1999;9:188\u201393.","journal-title":"Eur J Public Health"},{"key":"503_CR74","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1477-7525-2-55","volume":"2","author":"JW Varni","year":"2004","unstructured":"Varni JW, Sherman SA, Burwinkle TM, Dickinson PE, Dixon P. The PedsQL\u2122 family impact module: preliminary reliability and validity. Health Qual Life Outcomes. 2004;2:55.","journal-title":"Health Qual Life Outcomes"},{"key":"503_CR75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","volume":"10","author":"M Orme","year":"2007","unstructured":"Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health. 2007;10:54\u201360.","journal-title":"Value Health"},{"key":"503_CR76","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/rheumatology\/keh703","volume":"44","author":"G Kobelt","year":"2005","unstructured":"Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology. 2005;44:1169\u201375.","journal-title":"Rheumatology"},{"key":"503_CR77","unstructured":"Kobelt G, Lekander I,Santesson Nicolae Y. Access to innovative treatments for rheumatoid arthritis in New Zealand. A comparison with Australia and the UK. European Health Economics. 2010;1\u201378. www.arthritis.org.nz\/wp-content\/uploads\/2014\/05\/ACCESS-TO-INNOVATIVE-TREATMENTS-RA-FINAL.pdf . Accessed 23 Aug 2016."},{"key":"503_CR78","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095\u2013108.","journal-title":"Med Care"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0503-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T14:49:02Z","timestamp":1601045342000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-016-0503-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,26]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["503"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0503-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,26]]},"article-number":"119"}}